Role of brain natriuretic peptide in the diagnosis and management of heart failure: Current concepts

Journal of Cardiac Failure

Volumn 8, Issue 5, 2002, Pages 288-299

  Latini, Roberto ^a   Masson, Serge ^a   De Angelis, Noeleen ^a   Anand, Inder ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b VA MEDICAL CENTER   (United States)

Author keywords

Adrenomedullin; Angiotensin receptor blockade; Natriuretic peptides; Neurohormonal activation; Prognostic markers; Val HeFT

Indexed keywords

ADRENOMEDULLIN; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CELIPROLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FUROSEMIDE; ISOSORBIDE MONONITRATE; METOLAZONE; METOPROLOL; NEUROHORMONE; ORBOFIBAN; SPIRONOLACTONE; VALSARTAN; XAMOTEROL;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FAMILY; SCREENING TEST;

EID: 0036775056     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.0805288     Document Type: Article

References (106)

1. Harris P: Congestive cardiac failure: Central role of the arterial blood pressure. Br Heart J 1987;58:190-203
2. Anand I: Pathogenesis of salt and water retention in the syndrome of congestive heart failure. In Poole-Wilson P, Colucci W, eds: Heart Failure: Scientific Principles and Clinical Practice. Churchill Livingstone, London, 1996
3. Anand IS, Chugh SS: Mechanisms and management of renal dysfunction in heart failure. Curr Opin Cardiol 1997;12:251-258
4. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560
5. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113
6. Tikkanen I, Fyhrquist F, Metsarinne K, Leidenius R: Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985;2:66-69
7. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H: Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-758
8. Wilkins MR, Redondo J, Brown LA: The natriureticpeptide family. Lancet 1997;349:1307-1310
9. Wu AH: B-type natriuretic peptide and its clinical utility in patients with heart failure. MLO Med Lab Obs 2001;33:10-14
10. Zeidel ML: Hormonal regulation of inner medullary collecting duct sodium transport. Am J Physiol 1993;265:F159-F173
11. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44
12. Burnett JC Jr, Granger JP, Opgenorth TJ: Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984;247:F863-F866
13. Atarashi K, Mulrow PJ, Franco-Saenz R: Effect of atrial peptides on aldosterone production. J Clin Invest 1985;76:1807-1811
14. Stein BC, Levin RI: Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-923
15. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr: Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol 2000;35:796-801
16. Fiscus RR, Tu AW, Chew SB: Natriuretic peptides inhibit apoptosis and prolong the survival of serum-deprived PC12 cells. Neuroreport 2001;12:185-189
17. Hanks SK, Quinn AM, Hunter T: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988;241:42-52
18. Chinkers M, Garbers DL: The protein kinase domain of the ANP receptor is required for signaling. Science 1989;245:1392-1394
19. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inoyue K, Imura H: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412
20. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC Jr: Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689
21. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG: Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-417
22. Mäntymaa P, Vuolteenaho O, Marttila M, Ruskoaho H: Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993;133:1470-1473
23. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H: Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;69:1500-1506
24. Motwani JG, McAlpine H, Kennedy N, Struthers AD: Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-1113
25. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91
26. Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K: Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 1995;25:1105-1110
27. Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, Omiya K, Murayama M: Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J 2001;141:751-758
28. Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kubler W: Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989;21:1349-1353
29. Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, Noe A, Matern G, Kuebler W: Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-912
30. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH: Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 1986;38:1827-1833
31. Nakamura M, Arakawa N, Yoshida H, Makita S, Hiramori K: Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 1994;90:1210-1214
32. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, Ford I, McMurray JJ, Dargie HJ: Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice. Heart 1997;78:594-597
33. Davidson NC, Coutie WJ, Struthers AD: N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation 1995;91:1276-1277
34. Cheung BM, Kumana CR: Natriuretic peptides - Relevance in cardiovascular disease. JAMA 1998;280:1983-1984
35. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001;76:1111-1119
36. Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, Richards AM: Clearance receptors and endopeptidase: Equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 1997;273:H2372-H2379
37. Jougasaki M, Burnett JC Jr: Adrenomedullin: Potential in physiology and pathophysiology. Life Sci 2000;66:855-872
38. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H: Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158-2161
39. Nicholls MG, Lainchbury JG, Lewis LK, McGregor DO, Richards AM, Troughton RW, Yandle TG: Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides 2001;22:1745-1752
40. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, Ando K, Fujita T: Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002;105:106-111
41. Marumoto K, Hamada M, Hiwada K: Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Colch) 1995;88:551-556
42. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, Kugiyama K, Ogawa H, Okumura K, Ogawa Y, Nakao K: Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996;132:101-107
43. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, Ashida T, Sugiyama T, Hada Y, Kuwajima I, Nishinaga M, Akioka H, Nakajima O, Nagai R, Yazaki Y: Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001;51:585-591
44. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC Jr: The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-154
45. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;16:416-422
46. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-444
47. Masson S, Gorini M, Salio M, Lucci D, Latini R, Maggioni AP: Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators. Ital Heart J 2000;1:282-288
48. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A: Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-374
49. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13
50. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353
51. Hobbs F, Davis R, Roalfe A, Trawinski J, Davies M: Performance characteristics of N terminal pro brain natriuretic peptide (NT-ProBNP) and BNP assays in the diagnosis of heart failure in community settings. J Am Coll Cardiol 2001;37:1A-648A
52. Hobbs F, Davis R, Roalfe A, Kenkre J, Trawinski J, Davies M: Performance characteristics of N terminal pro brain natriuretic peptide (NT-proBNP) and BNP assays in the diagnosis of symptomatic and asymptomatic left ventricular systolic dysfunction in primary care. J Am Coll Cardiol 2001;37:1A-648A
53. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K: Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-135
54. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS: Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002;105:595-601
55. Latini R, Maggioni AP, Masson S: What does the future hold for BNP in cardiology? Heart 2001;86:601-602
56. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-385
57. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3):161-167
58. Singer DR, Buckley MG, Macgregor GA, Khaghani A, Banner NR, Yacoub MH: Raised concentrations of plasma atrial natriuretic peptides in cardiac transplant recipients. Br Med J (Clin Res Ed) 1986;293:1391-1392
59. Masters RG, Davies RA, Keon WJ, Walley VM, Koshal A, de Bold AJ: Neuroendocrine response to cardiac transplantation. Can J Cardiol 1993;9:609-617
60. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ: Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999;100:287-291
61. de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten A: The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001;79:705-714
62. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K: Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993;72:255-259
63. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy E, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Hamm P, Pfeffer MA: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994;24:583-591
64. Bonarjee VV, Omland T, Nilsen DW, Caidahl K, Sundsfjord JA, Dickstein K: Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: Relation to indices of cardiac and renal function. Br Heart J 1995;73:511-516
65. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-1929
66. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, Struthers AD: Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22
67. De Lemos J, Morrow D, Bentley J, Omland T, Sabatine M, McCabe C, Hall C, Cannon C, Braunwald E: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-1763
68. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-391
69. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA: Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-296
70. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA: The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-1183
71. Richards A, Doughty R, Nicholls M, MacMahon S, Sharpe N, Murphy J, Espiner E, Frampton C, Yandle T: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001;37:1A-648A
72. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-442
73. Hystad ME, Geiran OR, Attramadal H, Spurkland A, Vege A, Simonsen S, Hall C: Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand 2001;171:395-403
74. Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG: BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab 2002;13:151-155
75. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130
76. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604
77. Yoshimura M, Mizuno Y, Nakayama M, Sakamoto T, Sugiyama S, Kawano H, Soejima H, Hirai N, Saito Y, Nakao K, Yasue H, Ogawa H: B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002;112:716-720
78. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ: Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138:1126-1132
79. Baran D, Horn EM, Hryniewicz K, Katz SD: Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure. Drugs 2000;60:997-1016
80. Luchner A, Burnett JC, Jr., Jougasaki M, Hense HW, Riegger GA, Schunkert H: Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-1844
81. Colantonio D, Casale R, Desiati P, Giandomenico G, Bucci V, Pasqualetti P: Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. J Clin Pharmacol 1991;31:238-242
82. Bouissou P, Galen FX, Richalet JP, Lartigue M, Devaux F, Dubray C, Atlan G: Effects of propranolol and pindolol on plasma ANP levels in humans at rest and during exercise. Am J Physiol 1989;257:R259-R264
83. The RESOVLD Investigators: Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-384
84. Persson H, Rythén-Alder E, Melcher A, Erhardt L: Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: Double blind comparison of metoprolol and xamoterol. Br Heart J 1995;74:140-148
85. Persson H, Andréasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, Hall C, Erhardt L: Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 2002;4:73-82
86. Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K, Woo KS: Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: A double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74:502-507
87. Thibault G, Amiri F, Garcia R: Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol 1999;61:193-217
88. Christensen G, Aksnes G, Ilebekk A, Kiil F: Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergic stimulation, intracoronary Ca2+ infusion, and aortic constriction in pigs. Circ Res 1991;68:638-644
89. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36:S19-S23
90. Trachte G: Physiology of the clearance receptor. In Samson W, Levin ER, eds: Contemporary Endocrinology: Natriuretic Peptides in Health and Disease. Humana, Totowa, NJ, 1997, pp. 259-274
91. Brown LA, Nunez DJ, Wilkins MR: Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J Clin Invest 1993;92:2702-272
92. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675
93. Baruch L, Anand I, Cohen I, Ziesche S, Judd D, Cohn JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658-2664
94. van den Meiracker AH, Man int Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-812
95. Urata H, Nishimura H, Ganten D: Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16:79-85
96. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-227
97. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin converting enzyme - Cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem 2000;275:33238-33243
98. Tschope C, Gohlke P, Zhu YZ, Linz W, Scholkens B, Unger T: Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: Role of kinins. J Card Fail 1997;3:133-148
99. Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH: Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J Pharmacol Exp Ther 1999;288:742-751
100. Masson S, Maggioni A, Anand I, Latini R, Vago T, Glazer R, Spormann D, Tognoni G, Cohn Jobot V-HI: Contribution of a pharmacoepidemiological approach to neurohormonal profiling of patients with heart failure in Val-HeFT. Eur Heart J 2001;22:S536
101. Latini R, Anand I, Judd D, Cohn J, for the Val-HeFT investigators: Data presented at: 74th Scientific Sessions of the American Heart Association, 2001, Anaheim, California
102. Maggioni A, Anand I, Gottlieb S, Latini R, Tognoni G, Cohn J: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving ACE-inhibitors. J Am Coll Cardiol 2002:in press
103. Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol 2002;39(9):1414-1421
104. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-516
105. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M: Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: A potential of hormone-guided treatment. Am Heart J 2001;141:925-932
106. Schirmer H, Omland T: Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study. Eur Heart J 1999;20:755-763